Precision Value & Health’s Post

Precision Value and Health is now Precision AQ. The healthcare landscape is rife with obstacles. Bringing a therapy to market requires much more than money and brilliance - it requires access. Our new identity reflects the unification of nine organizations and our mission: empowering access to life-changing medicine for all. We've fused together the science (IQ) and empathy (EQ) from our diverse teams to create Precision Access Quotient (AQ), enabling greater access to the services, data, expertise, and scale clients need to remove barriers at every step along the therapy-to-patient journey. We invite you to learn more and explore how we define access in healthcare: https://lnkd.in/eskgBVfQ

“No matter how few or how many of our diverse specialist teams you engage with, you get the added value of our collective expertise across all disciplines to help guide you through what’s to come.” - Doug Fulling, President of Precision AQ. Precision AQ is more than just a new name; It's the culmination of years of strategic development and integration to create a single company that can provide the most comprehensive view of the healthcare journey -- and offer the services and insights needed at every step of the therapy-to-patient journey. Read how we're changing the blueprint for access online: https://lnkd.in/epwPYiY3

You’ve climbed the ladder, now take the next step… Get more out of your career as a Senior Engagement Business Analyst at Precision: https://lnkd.in/ejb4K5am PRECISIONxtract

Our Team was thrilled to attend and present at ISPOR US. From our sponsored reception with industry friends to presenting in short courses on Sunday, our experts were very busy! Several posters were presented throughout the conference including "Implementing the Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Model for Sickle-Cell Disease - A Case Study" ranking in the top 5% of posters. PRECISIONheor

You might be surprised by the biggest operational barrier for biosimilars. But with a lower price than its brand-name reference products, would the inconvenience be worth the reward? With a survey of 25 health plan stakeholders, Dan Danielson, Cynthia Miller and Christopher Terrone discover more than half of the participants feel confident their organization can switch to biosimilars. So, why aren’t they? Find out in their recent conversation with Managed Healthcare Executive. https://lnkd.in/e3zmR7Xe PRECISIONvalue

Panels, posters, papers. There is a lot to absorb at ASCO 2024. Maybe a coffee would help. Stop by ASCO Booth 35093 for a pick-me-up—and let our experts help you unpack everything you’ve learned. #ASCO2024

It takes specialized expertise to get a new onco-therapeutic to market. Our experts have it—we help life sciences companies navigate life-changing therapies through the commercialization process, ensuring they reach the patients who need them most. Visit Booth 35093 to learn more. #ASCO2024 #lifesciences

Let’s color the world cancer-free. Stop by the wall at ASCO Booth 35093 to pin on a ribbon representing your oncology specialty. For every ribbon, we will make a donation to St Jude’s Children's Research Hospital. Together, we’ll strengthen the fight against cancer. #ASCO2024 #oncology

We’re seeking a Resourcing Coordinator to support the optimization and utilization of our Evidence Solutions team. If you have a passion for resource and project management, apply today: https://lnkd.in/ejFzUcRk